Available in oral and injectable formulation, and, more recently, GLP-1R-GIPR co-agonists, such as tirzepatide (at 10 mg or 15 mg), are all recommended on the American Diabetes Association (ADA) Professional Practice Committee guidance for obesity and weight management for the prevention of type 2 diabetes [10]. This evidence concerns the gene GIPR and obesity due to melanocortin 4 receptor deficiency.